Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity
Chenghong Sun,Chenghong Sun,Yongkang Zhang,Mingfei Liu,Zhong Liu,Zhong Liu,Lihong Pan,Lihong Pan,Hongbao Liang,Hongbao Liang,Ning Liu,Shirong Li,Shirong Li,Dejun Niu,Dejun Niu,Xiangzi Li,Xiangzi Li,Bin Li,Bin Li,Lijuan Cui,Lijuan Cui,Jingchun Yao,Jingchun Yao,Xuefeng Xiao,Guimin Zhang,Guimin Zhang
DOI: https://doi.org/10.1016/j.biopha.2023.114495
IF: 7.419
2023-05-01
Biomedicine & Pharmacotherapy
Abstract:Constipation arising from the poor bowel movement is a rife enteric health problem. Shouhui Tongbian Capsule (SHTB) is a traditional Chinese medicine (TCM) which effectively improve the symptoms of constipation. However, the mechanism has not been fully evaluated. The purpose of this study was to evaluate the effect of SHTB on the symptoms and intestinal barrier of mice with constipation. Our data showed that SHTB effectively improved the constipation induced by diphenoxylate, which was confirmed by shorter first defecation time, higher internal propulsion rate and fecal water content. Additionally, SHTB improved the intestinal barrier function, which was manifested by inhibiting the leakage of Evans blue in intestinal tissues and increasing the expression of occludin and ZO-1. SHTB inhibited NLRP3 inflammasome signaling pathway and TLR4/NF-κB signaling pathway, reduced the number of proinflammatory cell subsets and increased the number of immunosuppressive cell subsets to relieve inflammation. The photochemically induced reaction coupling system combined with cellular thermal shift assay and central carbon metabolomics technology confirmed that SHTB activated AMPKα through targeted binding to Prkaa1 to regulate Glycolysis/Gluconeogenesis and Pentose Phosphate Pathway, and finally inhibited intestinal inflammation. Finally, no obvious toxicity related to SHTB was found in a repeated drug administration toxicity test for consecutive 13 weeks. Collectively, we reported SHTB as a TCM targeting Prkaa1 for anti-inflammation to improve intestinal barrier in mice with constipation. These findings broaden our knowledge of Prkaa1 as a druggable target protein for inflammation inhibition, and open a new avenue to novel therapy strategy for constipation injury.
pharmacology & pharmacy,medicine, research & experimental